Combination therapy for treatment of cancer
AssigneePlus Vitech, S.L.
InventorsFrancisco José LÓPEZ-HERNÁNDEZ, Felipe VOCES-SÁNCHEZ, Josep LAMARCA-CIURO, Yaremi QUIRÓS-LUIS, Anna ESTEVE-ARENYS, Laura HIRALDO-GONZÁLEZ, Manuel Vicente SALINAS-MARTÍN
Life of this patent
Estimating the term…
Abstract
The present invention relates to the treatment of cancer using a combination of (a) a NK inhibitor (b) a checkpoint inhibitor.
Claims20
A pharmaceutical composition which comprises:
- (a) a NK1 inhibitor;
- and
- (b) a checkpoint inhibitor;
- for use in treating cancer.
The pharmaceutical composition for use according to anyone of the preceding claims, wherein the checkpoint inhibitor blocks or inhibits one or more immune system checkpoints selected from:
- a. The interaction between PD-1 and PDL-1 and/or PD-1 and PDL-2;
- b. The interaction between CTLA-4 and CD86 and/or CTLA-4 and CD80;
- c. The interaction between B7-H3 and/or B7-H4 and their respective ligands;
- d. The interaction between HVEM and BTLA;
- e. The interaction between GALS and TIM3;
- f. The interaction between MHC class I or II and LAG3;
- and
- g. The interaction between MHC class I or II and KIR
The pharmaceutical composition for use according to any one of the preceding claims, wherein the cancer is melanoma, lung cancer, renal cell carcinoma, lymphoma, squamous cell cancer, or urothelial carcinoma, preferably melanoma, renal cell carcinoma, lymphoma, squamous cell cancer, or urothelial carcinoma, most preferably melanoma.
The pharmaceutical composition for use according to any one of the preceding claims, wherein at least 1% of the cells in a tumour of the cancer express PD-1 and/or PD1-1, as determined by immunohistochemistry.
Dependencies are inferred from the claim text.